加载中
NYSEHealthcareMedical - Instruments & Supplies
最新数据
US$17.30
+US$0.15 · +0.87%
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
前收盘价
US$17.30
+US$0.15 · +0.87%
盘中时间采用ET。市场数据可能有所延迟。
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
日内区间
当前US$17.30
52周区间
当前US$17.30
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
52
合理估值
情绪
57
多空交织
风险
31
中等风险
动量
41
中性
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
日内区间
当前US$17.30
52周区间
当前US$17.30
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$20.83
上涨空间 20.40%报告持有此股票敞口的交易所交易基金。
Ballast Small/Mid Cap ETFMGMT243.07万1.48%1.65亿 USD1.17%US$49.185-0.14%
Dimensional World ex U.S. Core Equity 2 ETFDFAX26.04万0.00%123.36亿 USD0.28%US$37.08+0.76%
Invesco RAFI Developed Markets ex-U.S. Small-Mid ETFPDN15.96万0.05%3.47亿 USD0.47%US$45.715+0.83%
Gotham 1000 Value ETFGVLU10.57万0.04%2.46亿 USD0.65%US$27.555-0.02%
Dimensional - International Core Equity 2 ETFDFIC4.39万0.00%150.17亿 USD0.22%US$37.53+0.64%
BNY Mellon US Small Cap Core Equity ETFBKSE2.88万0.03%8417.42万 USD0.04%US$41.8954+0.42%Ballast Small/Mid Cap ETFMGMTDimensional World ex U.S. Core Equity 2 ETFDFAXInvesco RAFI Developed Markets ex-U.S. Small-Mid ETFPDNGotham 1000 Value ETFGVLUDimensional - International Core Equity 2 ETFDFICBNY Mellon US Small Cap Core Equity ETFBKSEAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
